Relmada Therapeutics Appoints Renowned Urologic Oncologist Dr. Yair Lotan As Chair Of Clinical Advisory Board To Advance NDV-01 Development

Relmada Therapeutics, Inc., a clinical-stage biotechnology company focused on developing innovative treatments for oncology and central nervous system disorders, has announced the appointment of Dr. Yair Lotan as Chair of its Clinical Advisory Board. Dr. Lotan, a highly respected urologic oncologist, will play a key role in guiding the clinical strategy for Relmada’s lead oncology candidate, NDV-01, as the company prepares to launch a Phase 3 trial in the first half of 2026.

Dr. Lotan brings over 20 years of experience in the field of bladder cancer, combining clinical practice, research, and academic leadership. He is widely recognized for his expertise in molecular biomarkers and has contributed to the development of clinical practice guidelines for bladder cancer management. His work also includes research in health economics and outcomes, positioning him as a valuable leader in shaping the company’s clinical advisory direction.

Sergio Traversa, Chief Executive Officer, Relmada, stated, “We believe that Yair’s first-hand understanding of the current treatment challenges in bladder cancer, combined with his deep clinical development expertise, will help to strengthen and enrich the clinical development program for NDV-01. As we prepare to advance NDV-01 to Phase 3 studies, we are confident that Yair’s leadership of our Clinical Advisory Board and his prominent role in the bladder cancer community will help to position the program for success.”

Raj Pruthi, MD, Chief Medical Officer-Urology, Relmada, said, “In my experience, a Clinical Advisory Board can play a vital role in the progression of an innovative product candidate, providing scientific insights and strategic advice. Relmada’s goal is to bring NDV-01 to patients with non-muscle invasive bladder cancer (NMIBC) as soon as possible. We are very pleased to have Yair on board to Chair Relmada’s Clinical Advisory Board. His influential thought-leadership will help Relmada to optimize our product development plan for NDV-01.”

Dr. Lotan, CAB Chair, Relmada, mentioned, “In my view, impressive initial Phase 2 data presented at AUA 2025 solidly support NDV-01’s unique potential to become a class-leading, bladder-sparing therapy for the treatment of NMIBC. While the combination of gemcitabine/docetaxel (Gem/Doce) has been embraced by the medical community, it is difficult to formulate the combination outside of a hospital setting. NDV-01’s simple, ready-to-use sustained release formulation could enable wider patient adoption and transform the care of NMIBC. I am excited to Chair the Clinical Advisory Board at this pivotal time for Relmada.”

The appointment follows the positive results from a Phase 2 trial of NDV-01, which were presented at the American Urology Association (AUA) Annual Meeting on April 28, 2025. As Chair of the Clinical Advisory Board, Dr. Lotan is expected to support the advancement of NDV-01 through late-stage development and provide strategic input on broader clinical initiatives within Relmada’s pipeline. His leadership is anticipated to strengthen Relmada’s efforts in developing effective therapies for bladder cancer and enhance the company’s ongoing focus on advancing impactful treatments in oncology.